Q-omics provides the consensus-scored SLC5A12 profile across patient tissues and cancer cell-line models. SLC5A12 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC5A12 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, SLC5A12 RNA expression shows 14,221 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where SLC5A12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC5A12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC5A12 survival associations across molecular data types. SLC5A12 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC5A12 RNA expression–survival associations across cancer types. High SLC5A12 expression shows unfavorable associations in MESO, but favorable associations in KIRC, SCLC, READ, LGG and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC5A12 RNA expression.
This table summarizes SLC5A12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC5A12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC5A12 shows lower tumor expression in KIRP and KICH and higher tumor expression in HNSC, LUSC, LUAD and BRCA. The HNSC box plot shows higher SLC5A12 RNA expression in tumor versus normal tissue (log2 FC = +1.118, t-test p < 0.001).
This table shows molecular features associated with SLC5A12 in patient tissues and cancer cell lines. In patient samples, SLC5A12 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC5A12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_SCLC.
